These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38763080)

  • 1. Implication of the endocannabidiome and metabolic pathways in fragile X syndrome pathophysiology.
    Dionne O; Abolghasemi A; Corbin F; Çaku A
    Psychiatry Res; 2024 Jul; 337():115962. PubMed ID: 38763080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysine acetylome profiling in mouse hippocampus and its alterations upon FMRP deficiency linked to abnormal energy metabolism.
    Wu YY; Yang C; Yan HJ; Lu P; Zhang L; Feng WC; Long YS
    J Proteomics; 2022 Oct; 269():104720. PubMed ID: 36089189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.
    Pei YP; Wang YY; Liu D; Lei HY; Yang ZH; Zhang ZW; Han M; Cheng K; Chen YS; Li JQ; Cheng GR; Xu L; Wu QM; McClintock SM; Yang Y; Zhang Y; Zeng Y
    J Neurosci; 2020 Feb; 40(6):1355-1365. PubMed ID: 31882402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.
    De Rubeis S; Fernández E; Buzzi A; Di Marino D; Bagni C
    Adv Exp Med Biol; 2012; 970():517-51. PubMed ID: 22351071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The state of synapses in fragile X syndrome.
    Pfeiffer BE; Huber KM
    Neuroscientist; 2009 Oct; 15(5):549-67. PubMed ID: 19325170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteome profiling of the prefrontal cortex of Fmr1 knockout mouse reveals enhancement of complement and coagulation cascades.
    Gao MM; Shi H; Yan HJ; Long YS
    J Proteomics; 2023 Mar; 274():104822. PubMed ID: 36646274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synaptic vesicle dynamic changes in a model of fragile X.
    Broek JAC; Lin Z; de Gruiter HM; van 't Spijker H; Haasdijk ED; Cox D; Ozcan S; van Cappellen GWA; Houtsmuller AB; Willemsen R; de Zeeuw CI; Bahn S
    Mol Autism; 2016; 7():17. PubMed ID: 26933487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuron-Specific FMRP Roles in Experience-Dependent Remodeling of Olfactory Brain Innervation during an Early-Life Critical Period.
    Golovin RM; Vest J; Broadie K
    J Neurosci; 2021 Feb; 41(6):1218-1241. PubMed ID: 33402421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.
    Sheridan SD; Theriault KM; Reis SA; Zhou F; Madison JM; Daheron L; Loring JF; Haggarty SJ
    PLoS One; 2011; 6(10):e26203. PubMed ID: 22022567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Deletion of Astroglial FMRP Dysregulates Glutamate Transporter GLT1 and Contributes to Fragile X Syndrome Phenotypes In Vivo.
    Higashimori H; Schin CS; Chiang MS; Morel L; Shoneye TA; Nelson DL; Yang Y
    J Neurosci; 2016 Jul; 36(27):7079-94. PubMed ID: 27383586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion of Fmr1 in parvalbumin-expressing neurons results in dysregulated translation and selective behavioral deficits associated with fragile X syndrome.
    Kalinowska M; van der Lei MB; Kitiashvili M; Mamcarz M; Oliveira MM; Longo F; Klann E
    Mol Autism; 2022 Jun; 13(1):29. PubMed ID: 35768828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragile X syndrome: From protein function to therapy.
    Bagni C; Oostra BA
    Am J Med Genet A; 2013 Nov; 161A(11):2809-21. PubMed ID: 24115651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome.
    Qin M; Zeidler Z; Moulton K; Krych L; Xia Z; Smith CB
    Behav Brain Res; 2015 Sep; 291():164-171. PubMed ID: 25979787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain Cholesterol Biosynthetic Pathway Is Altered in a Preclinical Model of Fragile X Syndrome.
    Parente M; Tonini C; Buzzelli V; Carbone E; Trezza V; Pallottini V
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome.
    Lovelace JW; Wen TH; Reinhard S; Hsu MS; Sidhu H; Ethell IM; Binder DK; Razak KA
    Neurobiol Dis; 2016 May; 89():126-35. PubMed ID: 26850918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Channelopathies in fragile X syndrome.
    Deng PY; Klyachko VA
    Nat Rev Neurosci; 2021 May; 22(5):275-289. PubMed ID: 33828309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing our understanding of human cognition through the study of Fragile X Syndrome.
    Cook D; Nuro E; Murai KK
    Dev Neurobiol; 2014 Feb; 74(2):147-77. PubMed ID: 23723176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The translational regulator FMRP controls lipid and glucose metabolism in mice and humans.
    Leboucher A; Pisani DF; Martinez-Gili L; Chilloux J; Bermudez-Martin P; Van Dijck A; Ganief T; Macek B; Becker JAJ; Le Merrer J; Kooy RF; Amri EZ; Khandjian EW; Dumas ME; Davidovic L
    Mol Metab; 2019 Mar; 21():22-35. PubMed ID: 30686771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model.
    Davidovic L; Navratil V; Bonaccorso CM; Catania MV; Bardoni B; Dumas ME
    Genome Res; 2011 Dec; 21(12):2190-202. PubMed ID: 21900387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BDNF in fragile X syndrome.
    Castrén ML; Castrén E
    Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.